KR940006531B1 - Process for preparation of pyridine derivatives - Google Patents
Process for preparation of pyridine derivatives Download PDFInfo
- Publication number
- KR940006531B1 KR940006531B1 KR1019910015150A KR910015150A KR940006531B1 KR 940006531 B1 KR940006531 B1 KR 940006531B1 KR 1019910015150 A KR1019910015150 A KR 1019910015150A KR 910015150 A KR910015150 A KR 910015150A KR 940006531 B1 KR940006531 B1 KR 940006531B1
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- group
- compound
- pyridine
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
내용 없음.No content.
Description
본 발명은 오메프라졸 제조용의 중요한 중간체인 다음 일반식(I')로 표시되는 피리딘 유도체의 제조방법에 관한 것이다.The present invention relates to a process for the preparation of pyridine derivatives represented by the following general formula (I '), which is an important intermediate for preparing omeprazole.
위 식에서, X는 메톡시기 또는 할로겐을 나타낸다.In the above formula, X represents a methoxy group or halogen.
오메프라졸 및 그 유도체는 위산분비억제 작용이 매우 우수하여 웨궤양 및 십이지장궤양을 포함하여 위장의 염증질환을 치료하는데 유용하며, 다음의 구조식을 갖는다.Omeprazole and its derivatives are excellent in inhibiting gastric acid secretion and are useful for treating gastrointestinal inflammatory diseases, including wee ulcer and duodenal ulcer, and have the following structural formula.
위 식에서, A 및 B는 같거나 다르며, 각각 수소, 알킬, 할로겐 카르보메톡시, 알콕시 또는 알카노일을 나타내며, 이때 A가 5-메톡시기이고 B가 수소인 화합물이 오메프라졸이다.Wherein A and B are the same or different and each represents hydrogen, alkyl, halogen carbomethoxy, alkoxy or alkanoyl, wherein the compound in which A is a 5-methoxy group and B is hydrogen is an omeprazole.
본 발명의 위 일반식(I')의 화합물은 오에프라졸 및 유도체를 합성하는데 중요한 중간체로서 이를 합성하는 것은 오메프라졸 및 그 유도체를 제조하는데 있어서 매우 중요한 일이다.The compound of the general formula (I ′) of the present invention is an important intermediate for synthesizing oeprazole and derivatives, which is very important in preparing omeprazole and its derivatives.
한국특허공고 제88-91호에는 위 일반식(I')유도체의 화합물을 합성하는 방법이 개시되어 있다. 예를 들면,2,3,5-콜리딘 등과 같은 피리딘 유도체를 출발물질로 하여 피리딘 환의 각 위치에 선택적으로 적당한 기를 도입하는 합성경로를 거치는 관계로 반응조작이 복잡하고 합성조건이 까다로운 단점이 있다. 이를 반응식으로 나타내면 아래와 같다. 최종 생성물인 2-하이드록시메틸 피리딘 유도체는 다시 할로겐 등과 반응시켜 피리딘 메틸 라디칼화함으로써 오메프라졸 제조용 피리딘 유도체를 합성하고 있다.Korean Patent Publication No. 88-91 discloses a method for synthesizing a compound of the above general formula (I ') derivative. For example, the reaction operation is complicated and the synthesis conditions are difficult due to the synthetic route of selectively introducing a suitable group at each position of the pyridine ring by using a pyridine derivative such as 2,3,5-collidine as a starting material. . This is represented by the following reaction scheme. The final product, 2-hydroxymethyl pyridine derivative, is further reacted with halogen or the like to pyridine methyl radical to synthesize pyridine derivative for preparing omeprazole.
이와 같은 기존의 특허 방법은, 첫째, 출발물질로 사용하는 2,3,5-콜리딘 등과 피리딘 유도체의 합성이 치환되어진 메틸의 위치상 쉽지 않으며, 실제 3,5-루티딘과 같은 물질을 출발물질로 2번 위치에 선택적으로 알킬기를 도입하는 반응이 선행되어야 한다.This conventional patent method, first, the synthesis of 2,3,5-collidine and pyridine derivatives used as starting material is not easy to position the substituted methyl, in fact starting materials such as 3,5-lutidine The reaction to selectively introduce an alkyl group at position 2 into the material must be preceded.
둘째, 전체 합성경로가 피리딘 환의 각 위치에 적당한 기를 선택적으로 도입하기 위한 산화, 환원, 도입, 1환반응의 연속 조작으로 반응조작이 복잡하고 까다로운 합성조건을 갖고 있다.Secondly, the overall synthesis route has complex and difficult synthesis conditions due to the continuous operation of oxidation, reduction, introduction, and monocyclic reaction for selectively introducing an appropriate group at each position of the pyridine ring.
따라서, 출발물질을 피리딘 유도체에서 선택하여 각 위치에 적합한 기를 선택적으로 도입하는 합성경로를 택함으로 인해서 공정이 길고, 합성조건이 까다로울 뿐만 아니라 출발물질의 제조원가가 비싼 단점이 있다.Therefore, the process is long due to the selection of the starting material in the pyridine derivative and the selective introduction of a suitable group at each position, the process is long, the synthesis conditions are difficult, and the manufacturing cost of the starting material is expensive.
그러나 본 발명에서는 이미 각각의 적당한 위치에 원하는 기로 치환되어 있는 디엔과 디에노파일로카르보이미드 계통의 화합물을 반응시켜 일반식(I′)의 화합물을 쉽게 합성할 수 있는 특징이 있다.However, the present invention is characterized in that a compound of the general formula (I ′) can be easily synthesized by reacting a diene and a dienopyrocarbodiimide compound already substituted with a desired group at each appropriate position.
본 발명자들은 다음과 같은 합성경로를 거쳐서 이미 적당한 위치에 이미 원하는 기들을 수용하고 있는 출발물질을 사용하여 반응시키면 곧바로 피리딘을 형성하여 간단히 목적하는 물질을 제조할 수 있다는 사실을 발견하여 본 발명을 완성하였다.The present inventors have completed the present invention by finding that the desired material can be prepared simply by forming pyridine as soon as the reaction is carried out using a starting material that already contains desired groups at a suitable position through the following synthetic route. It was.
위 식들에서, R1은 탄소수 1-6의 알킬옥시카르보닐기이며 R2는 메탄설포닐기이며, X는 앞에서 정의한 바와 같다.In the above formula, R 1 is an alkyloxycarbonyl group having 1 to 6 carbon atoms, R 2 is a methanesulfonyl group, and X is as defined above.
이때, R1은 탄소수 1-6의 알킬로써 카르복시기의 보호역할을 하며, R2는 p-톨루엔술포녈, 벤젠술포닐 또는 에탄술포닐 등과 같은 강한 전자 친화력을 가지는 기로 6원환 형성 반웅을 쉽게 일어나게 하여 주는 역할과 함께 제거될 때 피리딘 환의 탈수소화 반응을 도와 준다.At this time, R 1 is alkyl having 1-6 carbon atoms to protect the carboxyl group, and R 2 is a group having a strong electron affinity such as p-toluenesulfonyl, benzenesulfonyl or ethanesulfonyl, to easily cause 6-membered ring formation reaction. Along with their role, they aid in the dehydrogenation of the pyridine ring.
가장 바람직하게는 R1이 -COOBu이고, R2가 p-톨루엔술포닐기이다.Most preferably, R 1 is -COOBu and R 2 is a p-toluenesulfonyl group.
곧, 이이 적당한 위치에 원하는 기들이 도입되어 있는 구조식 (B)의 디엔 화합물과 구조식 (C)의 카르보이미드 계통의 물질을 반응시켜 구조식 (D)의 질소원자 1개가 포함된 헤테로방향촉 6원환 화합물을 제조하고 연속하여 하이드록실기의 존재하에 피리딘 환 형성 반응을 진행하면 R1의 가수분해와 R2의 이탈반응이 함께 일어나면서 쉽게 위 구조식 (I')의 오메프라졸 및 그 유도체의 제조용 중간체인 피리딘 유도체를 합성할 수 있다.That is, a heteroaromatic six-membered ring containing one nitrogen atom of formula (D) by reacting a diene compound of formula (B) and a carbodiimide compound of formula (C) with the desired groups introduced at an appropriate position thereof. When preparing the compound, and proceed with the pyridine ring forming reaction in the presence of a hydroxyl group by continuous while up with the hydrolysis and release reaction of the R 2 of the R 1 easily for manufacture of an intermediate of omeprazole and their derivatives of the above formula (I ') Pyridine derivatives can be synthesized.
이렇게 제조된 위 구조식 (I')의 화합물은 리튬알루미늄하이드라이드나 소디움보론하이드라이드 등과 같은 통상의 환원제로 환원시켜서 카르복실기를 상응하는 하이드록시메틸기로 전환시킬 수 있다.The compound of formula (I ′) thus prepared may be converted to the corresponding hydroxymethyl group by reduction with a conventional reducing agent such as lithium aluminum hydride or sodium boron hydride.
또한, 이렇게 제조된 상응하는 하이드록시메틸화합물은 통상의 할로겐화수소로 처리하여 상응하는 할로겐화메틸 화합물로 제조할 수 있다.In addition, the corresponding hydroxymethyl compounds thus prepared can be prepared with the corresponding methyl halide compounds by treatment with conventional hydrogen halides.
본 발명의 반응은 무수 염화알루미늄 등과 같은 촉매 존재하에 반응시킴이 바람직하다.The reaction of the present invention is preferably reacted in the presence of a catalyst such as anhydrous aluminum chloride or the like.
곧, 2-메틸-1-펜텐-3-온으로부터 구조식 (B)의 디엔 화합물을 합성하고 염화알루미늠을 촉매로하여 예를 들어, 구조식 (C)의 화합물의 하나인 N-n-부틸옥시카르보닐메틸렌-p-톨루엔술폰아미드와 반응시키면 구조식 (D)의 피리딘 화합물을 높은 수율로 얻고 이어서 이 반응 유도체들을 수산화나트륨이나 수산화칼륨 등과 같은 알칼리금속의 수산화물의 용액에 넣어서 반응시키면 구조식 (I')의 화합물이 쉽게 얻어지며, 필요하면 카르복실기를 통산의 환원제로 하이드록시메틸기로 환원시킨다.In other words, a diene compound of formula (B) was synthesized from 2-methyl-1-penten-3-one and aluminium chloride was used as a catalyst, for example, Nn-butyloxycarbonyl, which is one of compounds of formula (C). Reaction with methylene-p-toluenesulfonamide yields the pyridine compound of formula (D) in high yield and then the reaction derivatives are added to a solution of an alkali metal hydroxide such as sodium hydroxide or potassium hydroxide to react with the compound of formula (I '). Compounds are readily obtained and if necessary reduce the carboxyl group to the hydroxymethyl group with a reducing agent throughout.
본 발명에서 사용되는 출발물질인 N-n-부틸옥시카르보메틸렌-p-톨루엔술폰아미드 등은 공지의 방법으로 합성하여 사용하며, 반응물질로서 사용하는 물질의 하나인 3-메톡시-2-에틸-1,3-펜타디엔은 아래와 같이 2-메틸-1-펜텐-3-온에 트리에틸아민이나 트리메틸아민 및 메틸요오드를 반응시켜서 합성하여 사용한다. 마찬가지로 유사한 다른 반응물질이나 출발물질은 이들 반응과 유사한 방법으로 용이하게 제조하여 사용한다.Nn-butyloxycarbomethylene-p-toluenesulfonamide, which is a starting material used in the present invention, is synthesized by a known method and used as a reactant, 3-methoxy-2-ethyl- 1,3-pentadiene is synthesized by reacting 2-methyl-1-penten-3-one with triethylamine, trimethylamine and methyl iodine as follows. Similarly other reactants or starting materials are readily prepared and used in a similar manner to these reactions.
다음의 실시예로써 본 발명을 더욱 상세히 설명한다.The present invention is explained in more detail by the following examples.
[실시예 1'Example 1
n-부틸글리옥시레이트 130g과 N-술피닐-p-톨루엔술폰아미드 220g을 벤젠 1,000ml에 용해시키고, 여기에 염화알루미늄 45g이 니트로벤젠 250ml에 녹아있는 용액에 천천히 적하하면서 3시간 환류시켰다.130 g of n-butylglyoxylate and 220 g of N-sulfinyl-p-toluenesulfonamide were dissolved in 1,000 ml of benzene and refluxed for 3 hours while slowly dropping 45 g of aluminum chloride into a solution dissolved in 250 ml of nitrobenzene.
반응물을 상온으로 냉각시키고 증류수 250ml로 1회 세척하고 용매를 감압증류하여 제거한 후 10-3torr에서 비등점 130-135℃의 N-n-부틸옥시카르보닐에틸렌-p-톨루엔술폰아미드를 종류하여 190g의 순수한 물질을 얻었다.The reactant was cooled to room temperature, washed once with 250 ml of distilled water, and the solvent was distilled off under reduced pressure. Then, 190 g of pure Nn-butyloxycarbonylethylene-p-toluenesulfonamide with a boiling point of 130-135 ° C. was purified at 10 −3 torr. Material was obtained.
C13H17NO4S(283.4) :C 13 H 17 NO 4 S (283.4):
이론치 : C; 55.14, H; 6.12, N ; 5.04 S ; 11.14Theoretical: C; 55.14, H; 6.12, N; 5.04 S; 11.14
실측치 : C; 55.10 H; 6.05 N; 4.95 S ; 11.32Found: C; 55.10 H; 6.05 N; 4.95 S; 11.32
[실시예 2]Example 2
트리에틸아민 85g에 염화제1구리무수물 1.5g을 넣고 상온에서 1시간 교반시켜준 후, 이 용액을 2-메틸-1-펜텐-3-온 35g이 벤젠 85ml에 녹아있는 용액에 천천히 넣어 주었다.1.5 g of cupric chloride anhydride was added to 85 g of triethylamine, and the mixture was stirred at room temperature for 1 hour. The solution was slowly added to a solution of 35 g of 2-methyl-1-penten-3-one dissolved in 85 ml of benzene.
다시 반응용기에 메틸요오드 100g을 넣고 3시간 교반한 후 반응온도를 40℃로 하여 1시간 더 교반하여준후, 반응혼합물을 상온으로 냉각한 후 에테르로 추출하였다.100 g of methyl iodine was added to the reaction vessel and stirred for 3 hours, followed by stirring for 1 hour at 40 ° C., and the reaction mixture was cooled to room temperature and extracted with ether.
용매를 감압증류하여 제거한 후 감압증류하여 정제하여 10mmHg에서 45-49℃에서 증류되어 나오는 순수한 3-메톡시-2-메틸-펜타디엔을 27g 얻었다.The solvent was distilled off under reduced pressure, followed by distillation under reduced pressure to obtain 27 g of pure 3-methoxy-2-methyl-pentadiene distilled at 45-49 ° C. at 10 mmHg.
NMR(CDCl3) : 1.62(d,3H),1.70(s,3H),3.20(s,2H)3.68(s,3H), 4.79(q,1H)NMR (CDCl 3 ): 1.62 (d, 3H), 1.70 (s, 3H), 3.20 (s, 2H) 3.68 (s, 3H), 4.79 (q, 1H)
[실시예 3]Example 3
3-메톡시-2-메틸-펜타디엔 27g을 디크로에탄 250ml에 녹이고 염화알루미늄 10.7g을 넣어준 후 실시예 1에서 합성한 N-n-부틸옥시카르보닐에틸렌-p-톨루엔술폰아미드 68g을 상온에서 천천히 넣어주었다.After dissolving 27 g of 3-methoxy-2-methyl-pentadiene in 250 ml of dichloroethane and adding 10.7 g of aluminum chloride, 68 g of Nn-butyloxycarbonylethylene-p-toluenesulfonamide synthesized in Example 1 was prepared at room temperature. I put it slowly.
3시간동안 반응물을 교반하고 셀라이트 545로 여과한 후 용매를 감압증류하여 제거하고 에탄을 250ml와수산화칼륨 27g을 넣어 10시간 환류시켰다. 반응혼합물을 상온으로 냉각시키고 에테르로 추출하여 3,5-디메틸-4-메톡시 -피리딘-2-카르복실산 15g을 얻었다.The reaction mixture was stirred for 3 hours, filtered through Celite 545, the solvent was distilled off under reduced pressure, and 250 ml of ethane and 27 g of potassium hydroxide were added to reflux for 10 hours. The reaction mixture was cooled to room temperature and extracted with ether to give 15 g of 3,5-dimethyl-4-methoxy-pyridine-2-carboxylic acid.
NMR(CDCl3) : 2.21(s,3H),2.29(s,3H),3.81(s,3H), 4.56(br,1H), 8.18(s,1H)NMR (CDCl 3 ): 2.21 (s, 3H), 2.29 (s, 3H), 3.81 (s, 3H), 4.56 (br, 1H), 8.18 (s, 1H)
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019910015150A KR940006531B1 (en) | 1991-08-30 | 1991-08-30 | Process for preparation of pyridine derivatives |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019910015150A KR940006531B1 (en) | 1991-08-30 | 1991-08-30 | Process for preparation of pyridine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR930004267A KR930004267A (en) | 1993-03-22 |
| KR940006531B1 true KR940006531B1 (en) | 1994-07-21 |
Family
ID=19319381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019910015150A Expired - Fee Related KR940006531B1 (en) | 1991-08-30 | 1991-08-30 | Process for preparation of pyridine derivatives |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR940006531B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004098599A3 (en) * | 2003-05-06 | 2005-02-03 | Altana Pharma Ag | Proton pump inhibitors for the treatment of lower abdominal disorders |
-
1991
- 1991-08-30 KR KR1019910015150A patent/KR940006531B1/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004098599A3 (en) * | 2003-05-06 | 2005-02-03 | Altana Pharma Ag | Proton pump inhibitors for the treatment of lower abdominal disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| KR930004267A (en) | 1993-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4620008A (en) | Processes for the preparation of omeprazole and intermediates therefore | |
| JPH0592965A (en) | Production of alpha,beta-unsaturated ketolactone | |
| JP2731853B2 (en) | Method for producing tri-lower alkanoyloxyboron | |
| KR940006531B1 (en) | Process for preparation of pyridine derivatives | |
| JPH082821B2 (en) | 1,4,5,8-Tetrakis (hydroxymethyl) naphthalene derivative and method for producing the same | |
| US2953572A (en) | Pyridinecarboxylic acid 1-oxides | |
| JP2654516B2 (en) | Method for producing silicon azide compound | |
| JP2583062B2 (en) | Method for producing heterocyclic compound | |
| JPH061776A (en) | Production of substituted pyrazinecarbonitrile | |
| JPS61178999A (en) | organic gold compounds | |
| KR960005828B1 (en) | Method for preparing pyridine derivative | |
| JP2662162B2 (en) | Method for producing 3-alkylpyrrole | |
| JPH01238548A (en) | 1,4,5,8-tetrakis(hydroxymethyl)naphthalene, its derivative and production thereof | |
| US4808340A (en) | Process for preparing methyl 4-oxo-5-tetradecynoate | |
| US4031136A (en) | Process for the preparation of trans, trans-muconic acid | |
| JP2743198B2 (en) | Cyclopentanes | |
| JPS6026395B2 (en) | Synthesis method of N-trialkylsilylmethylurea | |
| JP2500316B2 (en) | 1,4,5,8-Tetrakis (halogenomethyl) naphthalene derivative and method for producing the same | |
| JPS5936633B2 (en) | Production method of benzocoumarin derivatives | |
| JPS6272661A (en) | Manufacture of 4-hydroxy-2-oxo-pyrrolidine-1-yl-acetamide | |
| JPS58167551A (en) | Preparation of carvacrol derivative | |
| JPH0535157B2 (en) | ||
| JPH0415233B2 (en) | ||
| JPH0460591B2 (en) | ||
| JPH08151405A (en) | Production of ester compound effective as electron-donating compound of ziegler/natta catalyst |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
St.27 status event code: A-0-1-A10-A12-nap-PA0109 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| AMND | Amendment | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| J2X1 | Appeal (before the patent court) |
Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL |
|
| PB0901 | Examination by re-examination before a trial |
St.27 status event code: A-6-3-E10-E12-rex-PB0901 |
|
| G160 | Decision to publish patent application | ||
| PG1605 | Publication of application before grant of patent |
St.27 status event code: A-2-2-Q10-Q13-nap-PG1605 |
|
| B701 | Decision to grant | ||
| PB0701 | Decision of registration after re-examination before a trial |
St.27 status event code: A-3-4-F10-F13-rex-PB0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U11-oth-PR1002 Fee payment year number: 1 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 19970722 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 19970722 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R13-asn-PN2301 St.27 status event code: A-5-5-R10-R11-asn-PN2301 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R13-asn-PN2301 St.27 status event code: A-5-5-R10-R11-asn-PN2301 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R13-asn-PN2301 St.27 status event code: A-5-5-R10-R11-asn-PN2301 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-4-4-P10-P22-nap-X000 |